All for Joomla All for Webmasters

ABOUT

MANAGEMENT

team

David T. Curiel, MD, PhD

Founder and CSO
  • 30+ years experience in academic research in USA, Europe, Asia
  • Recognized world expert in adenovirus
  • Two previous biotech start-up with successful exits
  • Extensive experience in bench-to-bed translation of adenovirus agents
team

Daniel Katzman

CEO
  • Serial entrepreneur and biotech executive
  • Founder and principal manager of several successful early state biotech companies in the Boston area
  • Experience in founding, funding and operating clinical stage biotech start ups

ADVISORS

team

Michael S. Diamond, MD, PhD

  • The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine
team

Dan Streblow, PhD

  • Associate Scientist at the Vaccine and Gene Therapy Institute and Research Assistant Professor at the Department of Molecular Microbiology and Immunology, Oregon Health and Science University
team

Robert Paulino, MD, PHD

  • Research Professor and Director of the Institute for Tropical Medicine and Global Health, Universidad Iberoamericana, Dominican Republic

PUBLICATIONS

Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL, Korokhov N, Kovesdi I, Pereboev AV et al
Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector
PloS one 2012, 7(10):e46981

https://www.ncbi.nlm.nih.gov/pubmed/?term=23056548 (download)

 

 

Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT et al
Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine
Cancer research 2011, 71(17):5827-5837
https://www.ncbi.nlm.nih.gov/pubmed/?term=21747119 (download)

 

Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O’Neill AM, de Gruijl TD et al

A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo
Vaccine 2009, 27(50):7116-7124
https://www.ncbi.nlm.nih.gov/pubmed/?term=19786146 (download)

 

Korokhov N, Noureddini SC, Curiel DT, Santegoets SJ, Scheper RJ, de Gruijl TD

A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system
Molecular pharmaceutics 2005, 2(3):218-223
https://www.ncbi.nlm.nih.gov/pubmed/?term=15934782 (download)

 

Belousova N, Korokhov N, Krendelshchikova V, Simonenko V, Mikheeva G, Triozzi PL, Aldrich WA, Banerjee PT, Gillies SD, Curiel DT et al

Genetically targeted adenovirus vector directed to CD40-expressing cells
Journal of virology 2003, 77(21):11367-11377
https://www.ncbi.nlm.nih.gov/pubmed/?term=14557622 (download)